Nasdaq
$1.17▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $157.4MShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 10.17Closed26.10.17 10:21SCHEDULE 13D/AOwnership#●●●
ALX ONCOLOGY HOLDINGS INC
VenBio Global Strategic Fund and related entities have entered into a joint filing agreement regarding ALX Oncology Holdings Inc. This agreement is intended to satisfy the joint filing requirements under Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934.…more
$1.17+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15After-hours26.10.16 05:558-KKey event
ALX ONCOLOGY HOLDINGS INC
ALX Oncology has entered into exchange agreements with certain stockholders to surrender 13,353,384 shares of common stock in exchange for pre-funded warrants to purchase an equivalent number of shares. The exchange is expected to settle on or about October 15, 2026, with the warrants carrying an exercise price of $0.001 per share.…more
$1.17+0.00%vs prev closeView filingShare - 8.18After-hours26.08.19 06:514Ownership
ALX ONCOLOGY HOLDINGS INC
Director Jason Lettmann of ALX Oncology Holdings Inc reported an insider transaction involving company securities on August 17, 2026. This filing formalizes the change in beneficial ownership via SEC Form 4.…more
$1.17+0.00%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.28Pre-market26.09.28 21:00#●●●#●●●#●●●
ALX Oncology Publishes ASPEN-06 Phase 2 Gastric Cancer Data in Nature Medicine…more
ALX Oncology announced the publication of Phase 2 clinical data for its lead candidate, evorpacept, in Nature Medicine, demonstrating significant clinical benefit in HER2-positive gastric cancer. However, the company will not pursue a Phase 3 trial for this indication independently and will instead seek development partnerships.…more
$1.17+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.2Pre-market26.09.02 21:00
●●●●●●●● ●●●●● ●●●●●●
ALX Oncology announced that its leadership will participate in fireside chats at three upcoming healthcare investor conferences in September. These sessions will provide updates on the company's clinical pipeline, though no specific material business developments were disclosed.…more
$1.17+0.00%vs prev close - 8.6Pre-market26.08.06 21:00
●●●●●●●● ●●●●● ●●●●●●
ALX 온콜로지는 주요 항암제 후보물질의 임상 시험이 계획대로 진행 중이며, 재무 구조 개선을 통해 2028년 상반기까지 운영 자금을 확보했다고 밝혔습니다. 신규 경영진 영입과 함께 차세대 ADC 치료제 개발에 속도를 내며 장기적인 기업 가치 제고에 집중하고 있습니다.…more
$1.17+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report